Skip to main content
. Author manuscript; available in PMC: 2019 Jul 22.
Published in final edited form as: Sci Transl Med. 2018 Oct 24;10(464):eaat0150. doi: 10.1126/scitranslmed.aat0150

Fig. 3. Cardiac glycosides as candidate drugs for groups 3 and 4 MB.

Fig. 3.

(A) Comparison of in vitro inhibition of cell viability predicted by DSNI-DFN versus CMAP-GSEA. MED8A cells were incubated for 72 hours at 10 μM with predicted drugs, after which cell viability was assessed. (B) Details of a drug cluster predicted to strongly inhibit cell viability in groups 3 and 4 MB. This cluster contains known anticancer compounds and multiple members of the cardiac glycoside family. (C) Ranked order of cardiac glycosides predicted by DSNI-DFN in groups 3 and 4 SHH and WNT MB. FDA, U.S. Food and Drug Administration. (D) Schematic of drug-drug (red) and drug-target (dark blue) interactions for the cardiac glycoside digoxin derived from the STITCH database.